{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:34:39Z","timestamp":1778855679983,"version":"3.51.4"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1160","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T23:13:20Z","timestamp":1393629200000},"page":"445-448","source":"Crossref","is-referenced-by-count":13,"title":["Gemcitabine-induced Hemolytic Uremic Syndrome Mimicking Scleroderma Renal Crisis Presenting with Raynaud's Phenomenon, Positive Antinuclear Antibodies and Hypertensive Emergency"],"prefix":"10.2169","volume":"53","author":[{"given":"Yuichiro","family":"Yamada","sequence":"first","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Nobata","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Kawai","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Wakamatsu","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Banno","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Carmichael J. The role of gemcitabine in the treatment of other tumours. Br J Cancer 78: 21-25, 1998.","DOI":"10.1038\/bjc.1998.750"},{"key":"2","unstructured":"2. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445, 1977."},{"key":"3","unstructured":"3. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol 27: 31-39, 2000."},{"key":"4","unstructured":"4. Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC. Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 89: 1895-1896, 1997."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Choi M, Woywodt A, G&ouml;bel U, Schneider W, Kettritz R. Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma. Nephrol Dial Transplant 14: 2523-2524, 1999.","DOI":"10.1093\/ndt\/14.10.2523"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85: 2023-2032, 1999.","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 40: E16, 2002.","DOI":"10.1053\/ajkd.2002.35758"},{"key":"8","unstructured":"8. M&uuml;ller S, Sch&uuml;tt P, Bojko P, et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 84: 110-114, 2005."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 100: 2664-2670, 2004.","DOI":"10.1002\/cncr.20290"},{"key":"10","unstructured":"10. Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP 6: 369-374, 2005."},{"key":"11","unstructured":"11. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 21: 3038-3045, 2006."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kalra N, Kad R, Osama S. Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma. Int J Clin Oncol 12: 385-387, 2007.","DOI":"10.1007\/s10147-007-0676-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Boeck S, Geiger S, Schulz C, Heinemann V. Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer. J Clin Gastroenterol 42: 551-552, 2008.","DOI":"10.1097\/MCG.0b013e31802da22e"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 24: 209-214, 2009.","DOI":"10.1002\/jca.20213"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Moake JL. Thrombotic microangiopathies. N Engl J Med 347: 589-600, 2002.","DOI":"10.1056\/NEJMra020528"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17: 5858-5866, 2011.","DOI":"10.1158\/1078-0432.CCR-11-0804"},{"key":"17","unstructured":"17. Clowse MEB, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 30: 1341-1343, 2003."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Marie I, Levesque H, Plissonnier D, Balguerie X, Cailleux N, Courtois H. Digital necrosis related to cisplatin in systemic sclerosis. Br J Dermatol 142: 833-834, 2000.","DOI":"10.1046\/j.1365-2133.2000.03448.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zaima C, Kanai M, Ishikawa S, et al. A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. Jpn J Clin Oncol 41: 803-806, 2011.","DOI":"10.1093\/jjco\/hyr045"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 51 (2 Suppl): S73-S76, 2004.","DOI":"10.1016\/j.jaad.2001.07.001"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Zemtsov A, Omueti-Ayoade K, Zemtsov R, Yang M. Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome. J Dermatol 39: 487-489, 2012.","DOI":"10.1111\/j.1346-8138.2011.01353.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mir-Bonaf&eacute; JM, Rom&aacute;n-Curto C, Santos-Briz A, Ca&ntilde;ueto J, Fern&aacute;ndez-L&oacute;pez E, Unamuno P. Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes. J Cutan Pathol 39: 707-711, 2012.","DOI":"10.1111\/j.1600-0560.2012.01918.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/5\/53_53.1160\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:50:23Z","timestamp":1621446623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/5\/53_53.1160\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1160","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}